Results 171 to 180 of about 21,002 (186)

Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis

Leukemia, 2017
Two major types of leukemogenic BCR-ABL fusion proteins are p190BCR-ABLand p210BCR-ABL. Although the two fusion proteins are closely related, they can lead to different clinical outcomes. A thorough understanding of the signaling programs employed by these two fusion proteins is necessary to explain these clinical differences.
J A, Cutler, R, Tahir, S K, Sreenivasamurthy, C, Mitchell, S, Renuse, R S, Nirujogi, A H, Patil, M, Heydarian, X, Wong, X, Wu, T-C, Huang, M-S, Kim, K L, Reddy, A, Pandey   +13 more
openaire   +2 more sources

Immunologic Evaluation of Peptides Derived From BCR/ABL-Out-of-Frame Fusion Protein in HLA A2.1 Transgenic Mice

Journal of Immunotherapy, 2012
Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphocytic leukemia express, besides the main BCR/ABL transcripts, novel BCR/ABL transcripts derived from alternative splicing between BCR exons 1, 13, or 14 with ABL exons 4 and 5. Their translational products present at C-terminus an amino acid portion derived from out-of-frame (
Casnici C, VOLPE, Gisella, Crotta K, Lattuada D, SAGLIO, Giuseppe, Marelli O.   +5 more
openaire   +2 more sources

Measurement of Free Circulating Bcr-Abl Fusion Protein and Its Phosphorylation in Patients with Chronic Myeloid Leukemia.

Blood, 2005
Abstract Diagnosis and monitoring of therapy in chronic myeloid leukemia (CML) depend on cytogenetic, FISH, and PCR assays for detecting the fusion bcr-abl gene. However, the there is an inherent variability and difficulty in standardizing quantitative PCR-based assays.
I. Jilani, H. Kantarjian, H. Faraji, M. Gorre, J. Cortes, O. Ottmann, K. Bhalla, S. O’Brien, F. Giles, M. Albitar   +9 more
openaire   +1 more source

TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization

Amino Acids, 2012
Chronic myeloid leukemia (CML) is a clonal hematologic malignancy characterized by the BCR-ABL protein. BCR-ABL is a constitutively active tyrosine kinase and plays a critical role in the pathogenesis of CML. Imatinib mesylate, a selective tyrosine kinase inhibitor, is effective in CML, but drug resistance and relapse occur. The coiled-coil (CC) domain
Zheng-Lan, Huang, Miao, Gao, Mao-Sheng, Ji, Kun, Tao, Qing, Xiao, Liang, Zhong, Jian-Ming, Zeng, Wen-Li, Feng   +7 more
openaire   +2 more sources

Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference

Leukemia Research, 2005
Nuclear topography, expression of the BCR/ABL fusion gene and its protein level/cellular pattern were studied in CML cell line K562 stimulated to differentiation, apoptosis and influenced by ABL-RNA interference (ABL-RNAi). Phorbol ester-induced maturation of K562 cells was accompanied by repositioning of down-regulated BCR/ABL genes closer to the ...
Eva, Bártová, Andrea, Harnicarová, Jirí, Pacherník, Stanislav, Kozubek   +3 more
openaire   +2 more sources

Flow cytometric bead assay of BCR-ABL fusion proteins in leukemia patients: An Indian experience.

Journal of Clinical Oncology, 2010
6595 Background: The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic myeloid leukemia (CML) and is present in a poor-risk subgroup of precursor B cell acut...
openaire   +1 more source

A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia

Leukemia Research, 2010
Despite initial remissions, most patients with Ph chromosome positive (Ph(+)) acute leukemia (AL) become refractory to tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib. This study was designed to determine if targeting the interleukin-3 receptor (IL-3R) with a diphtheria toxin fusion protein (DT(388)IL3) would improve the effectiveness ...
Hyun Pyo, Kim, Arthur E, Frankel, Donna E, Hogge   +2 more
openaire   +2 more sources

Alternative BCR/ABL Splice Variants in Philadelphia Chromosome–Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches

Cancer Research, 2007
Abstract Imatinib currently represents the standard treatment in the early chronic phase of chronic myelogenous leukemia (CML), thanks to the high percentage of cytogenetic complete remission achieved, but it is yet unclear to what extent it can eradicate leukemia.
Volpe G, Cignetti A, Panuzzo C, Kuka M, Vitaggio K, Brancaccio M, Perrone G, Rinaldi M, Prato G, Fava M, Geuna M, Pautasso M, Casnici C, Signori E, Tonon G, Tarone G, Marelli O, Fazio VM, Saglio G   +18 more
openaire   +6 more sources

HLA class II–restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia–derived dendritic cells to CD4+ T lymphocytes

Blood, 2001
Bcr-abl fusion peptide–specific CD4+ T-lymphocyte clones have recently been shown to augment colony formation by chronic myelogenous leukemia (CML) cells in a bcr-abl type-specific and HLA class II–restricted manner without addition of exogenous antigen.
M, Yasukawa, H, Ohminami, K, Kojima, T, Hato, A, Hasegawa, T, Takahashi, H, Hirai, S, Fujita   +7 more
openaire   +2 more sources

[Construction and expression of a vector containing protein transduction domain and bcr/abl fusion gene].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2002
To construct a vector containing protein transduction domain (PTD) and bcr/abl fusion gene of chronic myelogenous leukemia and express PTD-bcr/abl fusion protein in E. Coli.DNA fragment encoding PTD was synthesized and fused to PCR-amplified bcr/abl gene fragment, then inserted into plasmid pET-16b to get the expression vector pEPb containing PTD-bcr ...
Yingmin, Liang, Qiang, Sun, Shanshan, Jiang, Jizhu, Wang, Rongli, Wu, Ping, Chen, Li, Liu, Hua, Han   +7 more
openaire   +1 more source